XTX Topco Ltd Cuts Stock Holdings in Genmab A/S (NASDAQ:GMAB)

XTX Topco Ltd reduced its stake in shares of Genmab A/S (NASDAQ:GMAB) by 47.7% during the second quarter, Holdings Channel reports. The institutional investor owned 11,751 shares of the company’s stock after selling 10,705 shares during the quarter. XTX Topco Ltd’s holdings in Genmab A/S were worth $295,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Renaissance Technologies LLC increased its stake in Genmab A/S by 7.6% in the 2nd quarter. Renaissance Technologies LLC now owns 1,462,459 shares of the company’s stock worth $36,752,000 after purchasing an additional 103,859 shares during the period. Oppenheimer Asset Management Inc. increased its stake in shares of Genmab A/S by 26.3% in the second quarter. Oppenheimer Asset Management Inc. now owns 218,078 shares of the company’s stock worth $5,480,000 after buying an additional 45,376 shares during the period. Headlands Technologies LLC raised its holdings in Genmab A/S by 1,702.8% during the 2nd quarter. Headlands Technologies LLC now owns 5,138 shares of the company’s stock valued at $129,000 after buying an additional 4,853 shares during the last quarter. Choreo LLC purchased a new stake in Genmab A/S during the 2nd quarter valued at $776,000. Finally, Acadian Asset Management LLC grew its holdings in Genmab A/S by 360.8% in the 2nd quarter. Acadian Asset Management LLC now owns 38,010 shares of the company’s stock worth $954,000 after acquiring an additional 29,762 shares during the last quarter. Hedge funds and other institutional investors own 7.07% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on GMAB shares. JPMorgan Chase & Co. reaffirmed a “neutral” rating on shares of Genmab A/S in a research note on Tuesday, August 20th. BTIG Research lifted their price target on shares of Genmab A/S from $46.00 to $47.00 and gave the company a “buy” rating in a report on Thursday, June 27th. HC Wainwright reiterated a “buy” rating and set a $50.00 target price on shares of Genmab A/S in a report on Friday, September 20th. Morgan Stanley reaffirmed an “equal weight” rating and issued a $31.00 price target on shares of Genmab A/S in a research note on Wednesday, September 11th. Finally, Truist Financial lowered their price objective on Genmab A/S from $53.00 to $50.00 and set a “buy” rating for the company in a research report on Monday, September 9th. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and eight have given a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has an average rating of “Hold” and a consensus price target of $45.20.

Genmab A/S Price Performance

Shares of Genmab A/S stock opened at $24.33 on Friday. The stock has a market cap of $16.10 billion, a price-to-earnings ratio of 20.28, a PEG ratio of 0.73 and a beta of 0.99. Genmab A/S has a 1 year low of $23.80 and a 1 year high of $35.88. The firm’s 50-day moving average is $27.04 and its 200 day moving average is $27.84.

Genmab A/S (NASDAQ:GMAB) last issued its earnings results on Thursday, August 8th. The company reported $0.22 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.29 by ($0.07). The firm had revenue of $779.50 million during the quarter, compared to the consensus estimate of $734.60 million. Genmab A/S had a return on equity of 17.48% and a net margin of 29.06%. On average, equities analysts expect that Genmab A/S will post 1.27 EPS for the current fiscal year.

Genmab A/S Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.